NeuroCycle Therapeutics is developing its lead candidate, NCT10004, as a first-in-class, orally administered treatment of itch - particularly itch related to atopic dermatitis. NCT10004 quickly reduced itch in preclinical models and is expected to be broadly active across multiple pruritic indications including atopic dermatitis.
Undisclosed Orphan Epilepsy
We are currently concluding the discovery phase of a treatment for epilepsy.
GABAA Follow-On Program
A treatment currently in discovery would have multiple indications, such as Neuropathic pain, Panic Disorder, and others.